ANI Pharmaceuticals (ANIP) shares ended the last trading session 6.2% higher at $28.91. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.8% loss over the past four weeks.Last week, the company announced that the FDA has approved its abbreviated new drug application for Clorazepate Dipotassium tablets. The company’s Clorazepate Dipotassium tablets are the generic version of the Reference Listed Drug Tranxene. This might have been driving the share price rally.This drugmaker is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of -71.6%. Revenues are expected to be $70.2 million, up 44.4% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For ANI, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ANIP going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>ANI is part of the Zacks Medical - Biomedical and Genetics industry. Precision BioSciences (DTIL), another stock in the same industry, closed the last trading session 0.7% lower at $1.45. DTIL has returned -5.8% in the past month.For Precision BioSciences, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.43. This represents a change of -219.4% from what the company reported a year ago. Precision BioSciences currently has a Zacks Rank of #2 (Buy). Just Released: Zacks Top 10 Stocks for 2022 In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022? From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research